Nitric oxide targets in the guinea-pig intestine identified by induction of cyclic GMP immunoreactivity.
The immunohistochemical localization of cyclic GMP was used to determine potential physiological sites of action of nitric oxide in the guinea-pig small intestine and colon. In control tissue, cyclic GMP-immunoreactivity was observed only in macrophages, whose identity was confirmed by double-label experiments using either F4/80, a macrophage-specific antibody, or fluorescein isothiocyanate-labelled dextran injected intravenously. Following exposure to the nitric oxide donor, sodium nitroprusside, cyclic GMP-immunoreactivity was induced in subpopulations of neurons in the myenteric and submucosal plexuses of the ileum and colon. In the colon, cyclic GMP-immunoreactivity was induced in 5-10% of myenteric neurons. The cyclic GMP-immunoreactive neurons did not contain nitric oxide synthase. In the ileum, cyclic GMP-immunoreactive neurons comprised about 2% of myenteric neurons and 40% of submucosal neurons; these cyclic GMP-immunoreactive neurons were also immunoreactive for vasoactive intestinal peptide, but they did not contain nitric oxide synthase. Interstitial cells between the mesothelium and the longitudinal muscle layer, vascular smooth muscle and vascular pericytes also showed sodium nitroprusside-induced cyclic GMP-immunoreactivity. The interstitial cells of Cajal at the inner surface of the circular muscle layer and the smooth muscle cells of the circular and longitudinal muscle layers showed increases in cyclic GMP-immunoreactivity that varied in extent from animal to animal. The results suggest that nitric oxide could act at several sites in the intestine through the stimulation of guanylyl cyclase.
Young
H M
HM
Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Victoria, Australia.
McConalogue
K
K
Furness
J B
JB
De Vente
J
J
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000594:Amino Acid Oxidoreductases / Q000032:analysis; D000818:Animals; D003106:Colon / Q000166:cytology / Q000187:drug effects / Q000294:innervation*; D006152:Cyclic GMP / Q000032:analysis / Q000096:biosynthesis*; D003911:Dextrans; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives; D005725:Ganglia, Autonomic / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D006168:Guinea Pigs; D007082:Ileum / Q000166:cytology / Q000187:drug effects / Q000294:innervation*; D007150:Immunohistochemistry; D008264:Macrophages / Q000166:cytology / Q000502:physiology* / Q000648:ultrastructure; D016253:Microscopy, Immunoelectron; D009197:Myenteric Plexus / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009252:NADPH Dehydrogenase / Q000032:analysis; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase; D009599:Nitroprusside / Q000494:pharmacology*; D014660:Vasoactive Intestinal Peptide / Q000032:analysis
D003911:Dextrans; C015219:fluorescein isothiocyanate dextran; D009599:Nitroprusside; D009569:Nitric Oxide; D014660:Vasoactive Intestinal Peptide; D019001:Nitric Oxide Synthase; D000594:Amino Acid Oxidoreductases; D009252:NADPH Dehydrogenase; D006152:Cyclic GMP; D016650:Fluorescein-5-isothiocyanate; D015056:1-Methyl-3-isobutylxanthine